- Routes reviewed
- Subcutaneous injection and nasal spray
- Injection promotion
- $79 first month on a three-month plan; $149/month after
- Nasal purchase choices
- $125 monthly or $140 one-time advertised
- Support
- Provider messaging and check-ins advertised
- Delivery
- Free discreet shipping advertised
A catalog with more than one cost structure
AgelessRx offers several NAD+ delivery options, but this guide focuses on its injectable and nasal prescriptions. The injection page emphasizes a first-month promotion connected to a three-month plan. The nasal page presents a monthly subscription beside a one-time purchase. These are different purchasing decisions, even before considering differences in formulation or clinical suitability.
A reader should select the actual product and payment arrangement before comparing AgelessRx with another provider. A catalog's lowest headline number can otherwise make one route seem cheaper while silently carrying the terms of a different route or a longer commitment.
The injection promotion needs two numbers
The injection offer shows $79 for the first month and $149 per month afterward, with the offer applying to a three-month plan billed in full. The central budgeting point is that the introductory figure is not the continuing monthly rate. Confirm the full first invoice and the later invoice schedule at checkout, rather than assuming the promotion describes every month of the initial quarter.
A useful comparison sheet records the first payment, the period that payment covers and the next payment independently. If one entry is unknown, leave it open. Dividing an unverified quarter total into a monthly estimate creates false precision.
What the service promises to include
AgelessRx describes an online clinician evaluation, continuing messaging, check-ins and free shipping. The injection information also distinguishes different vial sizes. Those details let a reader ask more specific questions about what is being renewed and how an adjustment affects an existing shipment.
The company advertises pausing or cancelling the subscription. A pause is a scheduling feature, however, and should not be read as a promise to refund medication already dispensed. Get the processing cutoff and restart terms before travel or a planned break. The answer matters more than a general cancel-anytime label.
Research language needs careful reading
The provider publishes customer survey results and describes its research program. A self-reported improvement among responding customers can help describe that survey; it cannot isolate a drug effect from selection, expectations, concurrent changes or natural variation. Nor does a company's involvement in research establish that every item in its catalog has demonstrated the same outcome.
Read an individual study by formulation, route, comparator and measured endpoint. A blood-marker change or an oral-precursor experiment is not automatically evidence for cognitive improvement with nasal NAD+. Our product reviews retain that distinction instead of assigning a clinical score to the brand.
A sensible way to compare the brand
AgelessRx is especially worth examining when flexibility between a nasal one-time order and a subscription matters. Its injection offer requires a different cash-flow analysis because the promotional rate is linked to a longer billing arrangement. Neither structure is inherently preferable; the important question is whether the quoted commitment suits the patient's clinical plan and budget.
Before enrollment, request the exact dispensing pharmacy, the selected container size, the first and subsequent charges, and the policy if the prescriber changes the plan. Save the final offer rather than relying on a search result, which may continue showing an older introductory headline.
Useful distinctions
- Nasal subscription and one-time prices both displayed
- Ongoing provider messaging described
- Injection page distinguishes introductory and later rates
Limitations to weigh
- Injection headline is not the recurring rate
- Upfront three-month payment needs verification
- Customer surveys are not controlled efficacy trials
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.
- AgelessRx NAD+ Injection Provider
- AgelessRx NAD+ Nasal Spray Provider
- FDA: Compounding questions and answers Regulator
- Grant et al. 2019: Human plasma and urine metabolome during NAD+ IV infusion Clinical research